Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease
- PMID: 38872104
- PMCID: PMC11170808
- DOI: 10.1186/s12967-024-05348-8
Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease
Erratum for
-
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease.J Transl Med. 2023 Nov 21;21(1):837. doi: 10.1186/s12967-023-04731-1. J Transl Med. 2023. PMID: 37990219 Free PMC article.
References
-
- Bonig H, Verbeek M, Herhaus P, Braitsch K, Beutel G, Schmid C, Müller N, Bug G, Döring M, von Stackelberg A, Tischer J, Ayuk F, Wulf G, Holtick U, Pfeffermann L-M, Jahrsdörfer B, Schrezenmeier H, Kuci S, Zens A, Tribanek M, Zeiser R, Huenecke S, Bader P. Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease. J Transl Med. 2023;21:837. doi: 10.1186/s12967-023-04731-1. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources